ASCO 2025 Highlights: Innovent, RemeGen & Kelun Showcase Cutting-Edge Oncology Innovations

Recently, the ASCO official website has announced all selected abstract titles. The continuing popularity of ADCs and bispecific antibodies continues the trend of recent years. In the domestic ADC field, 36 studies covering 28 products were disclosed at ASCO, involving popular targets such as HER2, EGFR, and TROP2.

Kelun Biotech’s Six Clinical Study Results

1. TROP2 ADC SKB264
   Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.
   Abstract #: 8507
   Meeting date: June 1, 2025, 8:00–11:00 (US local time)
2. PD-L1 Antibody A167 + Chemotherapy
   Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.
   Abstract #: 6004
   Meeting date: May 31, 2025, 13:15–16:15 (US local time)
3. TROP2 ADC + PD-L1 SKB264 + A167
   Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study.
   Abstract #: 1019
   Meeting date: May 30, 2025, 14:45–16:15 (US local time)
4. TROP2 ADC + PD-L1 SKB264 + A167
   Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study.
   Abstract #: 8529
   Meeting date: May 31, 2025, 13:30–16:30 (US local time)
5. TROP2 ADC SKB264
   Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study.
   Abstract #: 8615
   Meeting date: May 31, 2025, 13:30–16:30 (US local time)
6. RET Inhibitor KL590586
   Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer.
   Abstract #: 6098

   Meeting date: June 2, 2025, 9:00–12:00 (US local time)

RemeGen’s Four Research Data

RemeGen’s 20+ oncology pipeline clinical progress or interim data have been selected for oral presentations, posters, or online displays, including Vedicitumab combination therapies as first-line treatment for HER2-expressing gastric cancer, Vedicitumab plus RC148 (PD-1/VEGF bispecific antibody) as first-line treatment for triple-negative breast cancer, and RC108 (c-Met ADC) plus TKI as second-line treatment for EGFR-mutant with MET overexpression NSCLC.

• Vedicitumab + Toripalimab + Chemotherapy/Trastuzumab first-line treatment for HER2-expressing locally advanced or metastatic gastric cancer clinical study
  Abstract #: LBA4012
  Meeting date: June 2, 2025 (Monday), 11:30–13:00
• RC108 + Poziotinib for locally advanced or metastatic EGFR-mutant with MET overexpressing NSCLC Ib/II clinical study
  Abstract #: 8592
  Meeting date: June 2, 2025 (Monday), 11:30–13:00
• Vedicitumab + RC148 vs. Nab-paclitaxel ± Toripalimab for HR-negative, HER2-low expressing unresectable locally advanced or metastatic breast cancer: an open-label, randomized, controlled phase II clinical study
  Abstract #: TPS1139
  Meeting date: June 2, 2025 (Monday), 9:00–12:00
• Vedicitumab + Pertuzumab ± Toripalimab neoadjuvant therapy for HER2-positive breast cancer safety and efficacy: an open-label phase II clinical study

  Abstract #: e12596

Duality Bio’s Two ADC Study Data

1. HER3 ADC DB-1310
   DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1/2a trial.
   Abstract #: 3000
   Meeting date: May 30, 2025, 14:45–14:57 (US local time, GMT-5)
2. B7H3 ADC DB-1311/BNT324
   DB?1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
   Abstract #: 5015

   Meeting date: June 1, 2025, 17:00–17:06 (US local time, GMT-5)

Innovent Biologics’ Multiple Oral Reports on IBI363 and IBI343

Innovent Biologics will present a series of clinical data for their innovative oncology pipeline at ASCO 2025, including multiple oral presentations on IBI363 (PD-1/IL-2α-bias bispecific antibody fusion protein) and IBI343 (CLDN18.2 ADC).

• Innovative PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 efficacy and safety in advanced acral and mucosal melanoma post immunotherapy
  Abstract #: 2502
  Presentation time: May 31, 2025, 3:00–6:00 PM (Central US time)
• IBI363 monotherapy or combined with bevacizumab efficacy and safety in advanced colorectal cancer patients
  Abstract #: 104
  Presentation time: June 1, 2025, 9:45–11:15 AM (Central US time)
• IBI363 in advanced NSCLC patients after immunotherapy
  Abstract #: 8509
  Presentation time: June 3, 2025, 9:45–11:15 AM (Central US time)
• Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): IBI343 phase I dose expansion cohort study results
  Abstract #: 4017
  Presentation time: June 2, 2025, 11:30 AM–1:00 PM (Central US time)
• Sintilimab (anti-PD-1) combined with ICE regimen second-line treatment for classical Hodgkin lymphoma (cHL): a multicenter, randomized, controlled, double-blind phase III study (ORIENT-21)
  Abstract #: 7007
  Presentation time: May 30, 2025, 2:45–5:45 PM (Central US time)
• Short-course radiotherapy combined with sintilimab and CAPOX as total neoadjuvant therapy for locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)
  Abstract #: 3519
  Presentation time: June 1, 2025, 11:30 AM–1:00 PM (Central US time)
• Dynamic tumor circulating DNA-driven nasopharyngeal carcinoma risk-adaptive systemic therapy (capecitabine/sintilimab): EP-STAR trial
  Abstract #: 6010

  Presentation time: June 2, 2025, 3:00–4:30 PM (Central US time)

Poster abstracts:

• PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 in mucosal and acral melanoma: multicenter, randomized, controlled, open-label phase II ongoing study
  Abstract #: TPS9594
  Presentation time: June 1, 2025, 9:00 AM–12:00 PM (Central US time)
• Anti-HER2 antibody-drug conjugate IBI354 in locally advanced unresectable or metastatic ovarian cancer: phase I updated results
  Abstract #: 5565
  Presentation time: June 1, 2025, 9:00 AM–12:00 PM (Central US time)
• IBI354 (anti-HER2 ADC) in HER2-positive breast cancer and other solid tumors: phase I updated study
  Abstract #: 1029
  Presentation time: June 2, 2025, 9:00 AM–12:00 PM (Central US time)
• Anti-TROP2 ADC IBI130 safety and efficacy in advanced triple-negative breast cancer (TNBC) and other solid tumors: phase I study results
  Abstract #: 1102
  Presentation time: June 2, 2025, 9:00 AM–12:00 PM (Central US time)
• Anti-Claudin18.2 (CLDN18.2) ADC arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G/GEJA): ongoing multi-region, randomized, controlled, open-label phase III study
  Abstract #: TPS4201
  Presentation time: May 31, 2025, 9:00 AM–12:00 PM (Central US time)
• Liver artery chemoembolization (TACE) combined with sintilimab (anti-PD-1), oxaliplatin and S-1, plus trastuzumab (HER2-positive) or apatinib (HER2-negative) as first-line treatment for gastric cancer liver metastases: phase II clinical study
  Abstract #: 4050

  Presentation time: May 31, 2025, 9:00 AM–12:00 PM (Central US time)